Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|June 1, 2014

BioPharm International

  • BioPharm International-06-01-2014
  • Volume 27
  • Issue 6

TOC Analyzer Increases Productivity

TOC Analyzer Increases Productivity

GE’s Sievers M9 Total Organic Carbon (TOC) Analyzer is designed to measure TOC in a range of samples from ultrapure water to process waters. GE offers the Sievers M9 TOC Analyzer in three versions: portable, online, or laboratory. The M9 Analyzer increases productivity by producing TOC results in two minutes. According to the company, the M9 enhancements promote simple operation and optimal data utilization. In addition, the M9 Analyzer can measure conductivity in grab sample or autosampler modes, an upgrade from the 900 TOC Analyzer series.

GE

Articles in this issue

over 12 years ago

A Sampling of New Tools for Downstream Processing

over 12 years ago

Finished Product Monographs in the European Pharmacopoeia

over 12 years ago

Global Expansion Shapes Drug Oversight

over 12 years ago

Bureaucratic Roadblocks Threaten Biopharma Growth

over 12 years ago

Outsourcing No Longer Just for Cost-Cutting

over 12 years ago

Challenges in Analytical Method Development and Validation

over 12 years ago

Brunei's Potential Pharmaceutical Market Growth

over 12 years ago

Assuring Equivalency of Alternative Lot-Release Test Methods

over 12 years ago

Handheld Analyzer Improves Accuracy

over 12 years ago

Concentrating Feed—an Applicable Approach to Improve Antibody Production

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more